Cargando…
Systemic therapies for unresectable locoregional melanoma: a significant area of need
Immune checkpoint inhibitors and BRAF-MEK inhibitors have revolutionized the management and prognosis of patients with metastatic melanoma. However, there is minimal evidence to guide their incorporation into current treatment paradigms for unresectable stage III disease. The era of effective system...
Autores principales: | Nan Tie, Emilia, Lai-Kwon, Julia E, Gyorki, David E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891929/ https://www.ncbi.nlm.nih.gov/pubmed/31807276 http://dx.doi.org/10.2217/mmt-2019-0010 |
Ejemplares similares
-
Locoregional melanoma: identifying optimal care in a rapidly changing landscape
por: Gyorki, David E, et al.
Publicado: (2019) -
Cryoablation in Locoregional Management of Complex Unresectable Chest Neoplasms
por: Iezzi, Roberto, et al.
Publicado: (2021) -
Efficacy of immune checkpoint inhibitors for in-transit melanoma
por: Nan Tie, Emilia, et al.
Publicado: (2020) -
Locoregional therapy combined with systemic therapy (LRT + ST) for unresectable and metastatic intrahepatic cholangiocarcinoma: a systematic review and meta-analysis
por: Zhang, Mengqi, et al.
Publicado: (2023) -
Prospective results of concurrent radiation therapy and weekly paclitaxel as salvage therapy for unresectable locoregionally recurrent breast cancer
por: Cai, Gang, et al.
Publicado: (2019)